Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
02:51pm, Friday, 29'th Nov 2024
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
12:46pm, Friday, 29'th Nov 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attr
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
10:05am, Thursday, 28'th Nov 2024
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
05:00pm, Wednesday, 27'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company's pivotal Phase 3 PURP
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.
04:24pm, Friday, 22'nd Nov 2024
BETHESDA, Md.--(BUSINESS WIRE)--The Children's Inn at the National Institutes of Health (NIH) today announced that Gilead Sciences Inc. has awarded The Inn a $1 million grant to support its renovation
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
11:45am, Wednesday, 20'th Nov 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ET Company Participants Dan O'Day - Chairman and CEO Andy Dickinson - CFO Conference Call Par
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
02:14pm, Friday, 15'th Nov 2024
On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81%
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
10:30am, Thursday, 14'th Nov 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
10:01am, Thursday, 14'th Nov 2024
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences to close Seattle office; shutdown impacts 72 employees
12:52am, Thursday, 14'th Nov 2024
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday.
Gilead Prices $3.5 Billion of Senior Unsecured Notes
08:24pm, Wednesday, 13'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today annou
Gilead initiated with a Buy at Citi
04:16pm, Wednesday, 13'th Nov 2024
Citi initiated coverage of Gilead with a Buy rating and $125 price target. The firm says that despite the stock's near-term outperformance, it remains bullish based primarily on upside from Biktarvy l
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
06:45am, Wednesday, 13'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is stud
GILD or VRTX: Which Is the Better Value Stock Right Now?
12:45pm, Tuesday, 12'th Nov 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presen
